Melinta secures $142M BARDA deal to target pediatric and 'biothreat' indications for antibiotics
Melinta Therapeutics secured a BARDA deal worth nearly $142 million to make two currently approved antibiotics available for children.
The deal comes roughly three years after Deerfield Management acquired the antibiotics company and tapped CEO Christine Ann Miller to restructure it. Despite the rising threat of antimicrobial resistance (AMR), Big Pharma has largely retreated from the high-risk field where many antibiotics fail in development while others languish due to a lack of available funding. The ones that do get approved are used sparingly to preserve efficacy and slow further resistance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.